| Acute bacterial skin and skin structure infection

Orbactiv vs Teflaro

Side-by-side clinical, coverage, and cost comparison for acute bacterial skin and skin structure infection.

Deep comparison between: Orbactiv vs Teflaro with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsTeflaro has a higher rate of injection site reactions vs Orbactiv based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Teflaro but not Orbactiv, including UnitedHealthcare

Category

Orbactiv

Teflaro

At A Glance

RouteIV infusion

FrequencySingle dose

ClassLipoglycopeptide antibacterial

RouteIV infusion

FrequencyEvery 12 hours

ClassCephalosporin antibacterial

Indications

Acute bacterial skin and skin structure infection

Acute bacterial skin and skin structure infection
Community-Acquired Pneumonia

Dosing

Acute bacterial skin and skin structure infection 1,200 mg as a single dose by IV infusion over 3 hours in patients 18 years and older.

Acute bacterial skin and skin structure infection Adults: 600 mg IV every 12 hours over 5 to 60 minutes for 5-14 days; pediatric patients >=2 years (>33 kg): 400 mg every 8 hours or 600 mg every 12 hours; pediatric patients >=2 years (<=33 kg): 12 mg/kg every 8 hours; 2 months to <2 years: 8 mg/kg every 8 hours; neonates (gestational age >=34 weeks, postnatal age >=12 days) to <2 months: 6 mg/kg every 8 hours over 30 to 60 minutes.

Community-Acquired Pneumonia Adults: 600 mg IV every 12 hours over 5 to 60 minutes for 5-7 days; pediatric patients >=2 years (>33 kg): 400 mg every 8 hours or 600 mg every 12 hours; pediatric patients >=2 years (<=33 kg): 12 mg/kg every 8 hours; 2 months to <2 years: 8 mg/kg every 8 hours over 5 to 60 minutes for 5-14 days.

Contraindications

Concomitant use of intravenous unfractionated heparin sodium within 120 hours (5 days) after ORBACTIV administration due to falsely elevated aPTT test results
Known hypersensitivity to oritavancin products

Known serious hypersensitivity to ceftaroline or other members of the cephalosporin class

Drug Interactions

971View drug interactions

1068View drug interactions

Adverse Reactions

Most common (>=3%) Headache, nausea, vomiting, limb and subcutaneous abscesses, diarrhea.

Serious Cellulitis, hypersensitivity reactions, infusion-related reactions, Clostridioides difficile-associated diarrhea, osteomyelitis.

Most common (>=2%) Diarrhea, nausea, rash, constipation, vomiting, increased transaminases, hypokalemia, phlebitis

Serious Hypersensitivity reactions, anaphylaxis, Clostridioides difficile-associated diarrhea, neurological adverse reactions (dizziness, convulsion), direct Coombs' test seroconversion

Postmarketing Agranulocytosis, leukopenia, eosinophilic pneumonia, encephalopathy, seizures

Pharmacology

Oritavancin is a semisynthetic lipoglycopeptide antibacterial that inhibits transglycosylation and transpeptidation steps of cell wall biosynthesis and disrupts bacterial membrane integrity, producing concentration-dependent bactericidal activity against susceptible Gram-positive organisms; antimicrobial activity correlates with the AUC/MIC ratio.

Ceftaroline is a cephalosporin antibacterial that exerts bactericidal activity by binding to essential penicillin-binding proteins (PBPs), including PBP2a in S. aureus and PBP2x in S. pneumoniae, and has in vitro activity against both Gram-positive and Gram-negative bacteria.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Orbactiv